Insights

More Articles Back to Article

EU approves anemia drug Reblozyl

The EU has approved Reblozyl, an erythroid maturation agent that treats anemia in patients with a rare blood cancer. The drug is manufactured by Bristol-Myers Squibb and was under development by Celegne before it merged with BMS. PMLive (UK) (6/29)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!